SN-38 Sensitizes BRCA-Proficient Ovarian Cancers to PARP Inhibitors through Inhibiting Homologous Recombination Repair

<div>SN-38 and olaparib combination exhibits no obvious toxicity in mice. (a) The body weights of mice in each group were weighed every week, and the weight change curve was made. (b) HE staining histological analysis of paraffin-embedded sections of the liver, spleen, and kidney in each group.</div>

Disease Markers

fig6

Figure 6

Figure 6: SN-38 Sensitizes BRCA-Proficient Ovarian Cancers to PARP Inhibitors through Inhibiting Homologous Recombination Repair 